# MSR22: Methodological approaches to assess cost-effectiveness using pathway models in oncology

### L Beggs<sup>1</sup>, K Lokuge<sup>1</sup>, N J Welton<sup>2</sup>, A Sadek<sup>2</sup>, L Claxton<sup>1</sup>

<sup>1</sup> National Institute for Health and Care Excellence, Manchester, UK. <sup>2</sup> University of Bristol, Bristol, UK

# References

#### **Evidence synthesis articles**

Lewis RA, Hughes D, Sutton AJ, Wilkinson C. Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions. *Pharmacoeconomics* 2021;**39**(1): 25-61

Incerti D, Jansen JP. PRM130 - open-source software for developing computationally efficient cost-effectiveness models to evaluate sequential treatment strategies in oncology. *Value in Health* 2018;**21**S378

Diaby V, Ali AA, Adunlin G, Kohn CG, Montero AJ. Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients. *Current Medical Research and Opinion* 2016;**32**(6): 991-996

Jansen JP, Incerti D, Linthicum MT. Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value Project. *Pharmacoeconomics* 2019;**37**(11): 1313-1320

Schettini F, Venturini S, Giuliano M, Lambertini M, Pinato DJ, Onesti CE, *et al.* Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer. *Cancer Treatment Reviews* 2022;**111**102-468

Stenner F, Chastonay R, Liewen H, Haile SR, Cathomas R, Rothermundt C, et al. A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. Oncology 2012;82(6): 333-340

#### Model structure articles

Tappenden P, Chilcott J, Brennan A, Squires H, Stevenson M. Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework. *Value in Health* 2012;**15**(8): 1127-1136

Tappenden P, Chilcott J, Brennan A, Squires H, Glynne-Jones R, Tappenden J. Using whole disease modeling to inform resource allocation decisions: economic evaluation of a clinical guideline for colorectal cancer using a single model. *Value in Health* 2013;**16**(4): 542-553

Zheng Y, Pan F, Sorensen S. Modeling Treatment Sequences in Pharmacoeconomic Models. *Pharmacoeconomics* 2017;**35**(1): 15-24

Lord J, Willis S, Eatock J, Tappenden P, Trapero-Bertran M, Miners A, *et al.* Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project. *Health Technology Assessment* 2013;**17**(58): 1-192

Jansen JP, Incerti D, Linthicum MT. Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value Project. *Pharmacoeconomics* 2019;**37**(11): 1313-1320

Huang M, Ramsey S, Xue W, Xie J, Pellissier J, Briggs A. Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence Models. *Pharmacoeconomics* 2022;**40**(3): 257-268

Blommestein HM, Verelst SG, de Groot S, Huijgens PC, Sonneveld P, Uyl-de Groot CA. A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model. *European journal of haematology* 2016;**96**(2): 198-208

Jin H, Tappenden P, Ling X, Robinson S, Byford S. A systematic review of whole disease models for informing healthcare resource allocation decisions. *PLOS ONE* 2023;**18**(9): e0291366